
CSG Systems International Reports First Quarter 2025 Results
DENVER--(BUSINESS WIRE)-- CSG (NASDAQ: CSGS) today reported results for the quarter ended March 31, 2025.
Raising 2025 Non-GAAP Profitability and EPS Guidance Targets; Reiterating All Others
Strong Cash Flow from Operations; Highest First Quarter Non-GAAP Adjusted Free Cash Flow Since 2018
Record High Revenue Diversification with 33% of Revenue Coming from Industry Verticals Outside of CSPs
Exciting Customer Wins and Contract Extensions including Mediacom, Liberty Latin America, and PLDT
Financial Results:
First quarter 2025 financial results:
Total revenue was $299.5 million.
GAAP operating income was $29.4 million, or an operating margin of 9.8%, and non-GAAP operating income was $51.5 million, or a non-GAAP adjusted operating margin of 19.0%.
GAAP earnings per diluted share (EPS) was $0.57 and non-GAAP EPS was $1.14.
Cash flows from operations were $11.5 million, with non-GAAP adjusted free cash flow of $7.1 million.
Shareholder Returns:
CSG declared its quarterly cash dividend of $0.32 per share of common stock, or a total of approximately $9 million, to shareholders.
During the first quarter of 2025, CSG repurchased a total of approximately 357,000 shares of its stock for approximately $22 million.
Business Activities:
In March 2025, CSG entered into a new credit agreement consisting entirely of a $600.0 million revolving credit facility, with a term through March 2030. The new credit agreement replaced CSG's existing credit agreement.
'Team CSG's strong first quarter results enabled us to raise our 2025 non-GAAP profitability and EPS guidance targets. We grew revenue nicely at customers outside of communication service providers ('CSPs') with a third of our revenue now coming from big, faster growing industry verticals providing a buffer against today's macro-economic uncertainty.' said Brian Shepherd, President and Chief Executive Officer of CSG. 'Our operating discipline and improving revenue mix resulted in Q1 2025 adjusted non-GAAP profitability expanding by over 240 basis points to 19% when compared to Q1 2024. And this improved profitability is contributing to excellent double-digit free cash flow growth with the midpoint of our 2025 cash flow guidance representing 15% year-over-year growth. With our steady sales wins, strong balance sheet, rich history of increasing our dividend for 12 consecutive years, and commitment to returning over $100 million in capital to shareholders in 2025, we believe CSG represents an excellent offensive and defensive choice for investors seeking stability and long-term value.'
For additional information and reconciliations regarding CSG's use of non-GAAP financial measures, please refer to the attached Exhibit 2 and the Investor Relations section of CSG's website at csgi.com.
Results of Operations
GAAP Results: Total revenue for the first quarter of 2025 was $299.5 million, a 1.5% increase when compared to revenue of $295.1 million for the first quarter of 2024. The increase in revenue can be mainly attributed to the revenue generated during the first quarter of 2025 from the businesses acquired during 2024.
GAAP operating income for the first quarter of 2025 was $29.4 million, or 9.8% of total revenue, compared to $31.8 million, or 10.8% of total revenue, for the first quarter of 2024. The decrease in GAAP operating margin can be mainly attributed to the $5.4 million increase restructuring and reorganization charges between years related to CSG's continued cost efficiency actions.
GAAP EPS for the first quarter of 2025 was $0.57, compared to $0.68 for the first quarter of 2024, with the decrease reflective of the higher restructuring and reorganization charges in 2025.
Non-GAAP Results: Non-GAAP operating income for the first quarter of 2025 was $51.5 million, or a non-GAAP adjusted operating margin of 19.0%, compared to $44.9 million, or a non-GAAP adjusted operating margin of 16.6% for the first quarter of 2024. The increase in non-GAAP operating margin can be mainly attributed to the cost efficiency actions taken during 2024 to optimize capacity and align resources to areas of the business with higher growth profiles.
Non-GAAP EPS for the first quarter of 2025 was $1.14, compared to $1.01 for the first quarter of 2024. The increase in non-GAAP EPS is mainly due to the higher non-GAAP operating income, discussed above, partially offset by foreign currency movements.
Balance Sheet and Cash Flows
Cash and cash equivalents as of March 31, 2025 were $136.0 million compared to $161.8 million as of December 31, 2024. CSG had net cash flows provided by (used in) operations for the first quarters ended March 31, 2025 and 2024 of $11.5 million and ($29.4) million, respectively, and had non-GAAP adjusted free cash flow (deficit) of $7.1 million and ($34.1) million, respectively.
Summary of Financial Guidance
For additional information and reconciliations regarding CSG's use of non-GAAP financial measures, please refer to the attached Exhibit 2 and the Investor Relations section of CSG's website at csgi.com.
Conference Call
CSG will host a conference call on Wednesday, May 7, 2025 at 5:00 p.m. ET, to discuss CSG's first quarter of 2025 earnings results. The call will be carried live and archived on CSG's website. A link to the conference call is available at http://ir.csgi.com. In addition, to reach the conference by phone, call 1-888-412-4131 and use the passcode 2327393.
Additional Information
For information about CSG, please visit CSG's website at csgi.com. Additional information can be found in the Investor Relations section of the website.
About CSG
CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.
Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.
Forward-Looking Statements
This news release contains forward-looking statements as defined under the Securities Act of 1933, as amended, that are based on assumptions about a number of important factors and involve risks and uncertainties that could cause actual results to differ materially from what appears in this news release. Some of these key factors include, but are not limited to the following items:
CSG derives a significant portion of its revenue from a limited number of customers, with approximately forty percent of its revenue from its two largest customers;
Fluctuations in credit market conditions, general global economic and political conditions, and foreign currency exchange rates;
CSG's ability to maintain a reliable, secure computing environment;
Continued market acceptance of CSG's products and services;
CSG's ability to continuously develop and enhance products in a timely, cost-effective, technically advanced and competitive manner;
CSG's ability to deliver its solutions in a timely fashion within budget, particularly large and complex software implementations;
CSG's dependency on the global telecommunications industry, and in particular, the North American telecommunications industry;
CSG's ability to meet its financial expectations;
Increasing competition in CSG's market from companies of greater size and with broader presence;
CSG's ability to successfully integrate and manage acquired businesses or assets to achieve expected strategic, operating and financial goals;
CSG's ability to protect its intellectual property rights;
CSG's ability to conduct business in the international marketplace;
CSG's ability to comply with applicable U.S. and International laws and regulations; and
CSG's business may be disrupted, and its results of operations and cash flows adversely affected by a global pandemic.
This list is not exhaustive, and readers are encouraged to review the additional risks and important factors described in CSG's reports on Forms 10-K and 10-Q and other filings made with the SEC.
March 31, 2025
December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents
$
136,024
$
161,789
Settlement and merchant reserve assets
274,228
343,235
Trade accounts receivable:
Billed, net of allowance of $4,152 and $3,041
265,174
266,903
Unbilled
87,719
80,173
Income taxes receivable
2,573
2,600
Other current assets
42,766
46,182
Total current assets
808,484
900,882
Non-current assets:
Property and equipment, net of depreciation of $137,571 and $133,514
63,659
56,595
Operating lease right-of-use assets
17,565
24,166
Software, net of amortization of $158,338 and $154,648
22,480
19,927
Goodwill
319,371
316,041
Acquired customer contracts, net of amortization of $137,719 and $133,279
36,679
39,377
Customer contract costs, net of amortization of $48,008 and $44,587
63,294
60,809
Deferred income taxes
75,757
73,295
Other assets
11,715
9,595
Total non-current assets
610,520
599,805
Total assets
$
1,419,004
$
1,500,687
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt
$
-
$
7,500
Operating lease liabilities
5,008
11,067
Customer deposits
36,928
41,448
Trade accounts payable
31,397
36,370
Accrued employee compensation
49,319
67,944
Settlement and merchant reserve liabilities
271,750
341,924
Deferred revenue
62,683
54,424
Income taxes payable
12,177
7,802
Other current liabilities
51,492
46,730
Total current liabilities
520,754
615,209
Non-current liabilities:
Long-term debt, net of unamortized discounts of $13,071 and $12,128
537,554
530,997
Operating lease liabilities
23,563
25,020
Deferred revenue
25,925
26,469
Income taxes payable
2,849
2,732
Deferred income taxes
99
94
Other non-current liabilities
25,165
17,597
Total non-current liabilities
615,155
602,909
Total liabilities
1,135,909
1,218,118
Stockholders' equity:
Preferred stock, par value $.01 per share; 10,000 shares authorized; zero shares issued and outstanding
-
-
Common stock, par value $.01 per share; 100,000 shares authorized; 29,104 and 28,854 shares outstanding
722
718
Additional paid-in capital
514,575
518,215
Treasury stock, at cost; 41,737 and 41,583 shares
(1,203,651
)
(1,194,224
)
Accumulated other comprehensive income (loss):
Cumulative foreign currency translation adjustments
(55,467
)
(62,290
)
Accumulated earnings
1,026,916
1,020,150
Total stockholders' equity
283,095
282,569
Total liabilities and stockholders' equity
$
1,419,004
$
1,500,687
Expand
CSG SYSTEMS INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS-UNAUDITED
(in thousands)
Quarter Ended
March 31, 2025
March 31, 2024
Cash flows from operating activities:
Net income
$
16,130
$
19,467
Adjustments to reconcile net income to net cash provided by (used in) operating activities-
Depreciation
5,013
5,636
Amortization
12,164
11,309
Loss on debt extinguishment
453
-
(Gain) loss on unrealized foreign currency transactions, net
522
(352
)
Deferred income taxes
(2,067
)
7,859
Stock-based compensation
8,404
7,736
Subtotal
40,619
51,655
Changes in operating assets and liabilities:
Trade accounts receivable, net
(4,838
)
(10,959
)
Other current and non-current assets and liabilities
(2,400
)
(9,827
)
Income taxes payable/receivable
4,529
(3,158
)
Trade accounts payable and accrued liabilities
(33,074
)
(59,581
)
Deferred revenue
6,633
2,519
Net cash provided by (used in) operating activities
11,469
(29,351
)
Cash flows from investing activities:
Purchases of software, property, and equipment
(4,401
)
(4,774
)
Receipts from sale of software, property, and equipment
152
-
Net cash used in investing activities
(4,249
)
(4,774
)
Cash flows from financing activities:
Proceeds from issuance of common stock
769
866
Payments of cash dividends
(9,460
)
(9,463
)
Repurchases of common stock
(22,396
)
(17,973
)
Deferred acquisition payments
(314
)
(488
)
Proceeds from long-term debt
150,625
-
Payments on long-term debt
(150,625
)
(1,875
)
Payments of debt financing costs
(2,258
)
-
Payments on financing obligations
(590
)
-
Settlement and merchant reserve activity
(70,211
)
(82,212
)
Net cash used in financing activities
(104,460
)
(111,145
)
Effect of exchange rate fluctuations on cash, cash equivalents, and restricted cash
2,488
(1,962
)
Net decrease in cash, cash equivalents, and restricted cash
(94,752
)
(147,232
)
Cash, cash equivalents, and restricted cash, beginning of period
506,763
463,876
Cash, cash equivalents, and restricted cash, end of period
$
412,011
$
316,644
Supplemental disclosures of cash flow information:
Cash paid during the period for-
Interest
$
10,181
$
10,898
Income taxes
2,964
3,288
Non-cash investing and financing activities-
Software, property, and equipment included in current and non-current liabilities
11,526
-
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents
$
136,024
$
120,810
Settlement and merchant reserve assets
274,228
192,962
Restricted cash included in current and non-current assets
1,759
2,872
Total cash, cash equivalents, and restricted cash
$
412,011
$
316,644
Expand
EXHIBIT 1
CSG SYSTEMS INTERNATIONAL, INC.
SUPPLEMENTAL REVENUE ANALYSIS
Revenue by Significant Customers: 10% or more of Revenue
Quarter Ended
Quarter Ended
Quarter Ended
March 31, 2025
December 31, 2024
March 31, 2024
Amount
% of Revenue
Amount
% of Revenue
Amount
% of Revenue
Charter
$
57,602
19
%
$
59,733
19
%
$
60,849
21
%
Comcast
52,759
18
%
58,935
19
%
52,804
18
%
Expand
Revenue by Vertical
Quarter Ended
Quarter Ended
Quarter Ended
March 31, 2025
December 31, 2024
March 31, 2024
Broadband/Cable/Satellite
50
%
51
%
51
%
Telecommunications
17
%
20
%
19
%
All other
33
%
29
%
30
%
Total revenue
100
%
100
%
100
%
Expand
Revenue by Geography
Quarter Ended
Quarter Ended
Quarter Ended
March 31, 2025
December 31, 2024
March 31, 2024
Americas
87
%
84
%
86
%
Europe, Middle East and Africa
9
%
10
%
9
%
Asia Pacific
4
%
6
%
5
%
Total revenue
100
%
100
%
100
%
Expand
EXHIBIT 2
CSG SYSTEMS INTERNATIONAL, INC.
DISCLOSURES FOR NON-GAAP FINANCIAL MEASURES
Use of Non-GAAP Financial Measures and Limitations
To supplement its condensed consolidated financial statements presented in accordance with generally accepted accounting principles (GAAP), CSG uses non-GAAP operating income, non-GAAP adjusted operating margin percentage, non-GAAP EPS, non-GAAP adjusted EBITDA, and non-GAAP adjusted free cash flow. CSG believes that these non-GAAP financial measures, when reviewed in conjunction with its GAAP financial measures, provide investors with greater transparency to the information used by CSG's management in its financial and operational decision making. CSG uses these non-GAAP financial measures for the following purposes:
Certain internal financial planning, reporting, and analysis;
Forecasting and budgeting;
Certain management compensation incentives; and
Communications with CSG's Board of Directors, stockholders, financial analysts, and investors.
These non-GAAP financial measures are provided with the intent of providing investors with the following information:
A more complete understanding of CSG's underlying operational results, trends, and cash generating capabilities;
Consistency and comparability with CSG's historical financial results; and
Comparability to similar companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures are not measures of performance under GAAP, and therefore should not be considered in isolation or as a substitute for GAAP financial information. Limitations with the use of non-GAAP financial measures include the following items:
Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles;
The way in which CSG calculates non-GAAP financial measures may differ from the way in which other companies calculate similar non-GAAP financial measures;
Non-GAAP financial measures do not include all items of income and expense that affect CSG's operations and that are required by GAAP to be included in financial statements;
Certain adjustments to CSG's non-GAAP financial measures result in the exclusion of items that are recurring and will be reflected in CSG's financial statements in future periods; and
Certain charges excluded from CSG's non-GAAP financial measures are cash expenses, and therefore do impact CSG's cash position.
CSG compensates for these limitations by relying primarily on its GAAP results and using non-GAAP financial measures as a supplement only. Additionally, CSG provides specific information regarding the treatment of GAAP amounts considered in preparing the non-GAAP financial measures and reconciles each n on-GAAP financial measure to the most directly comparable GAAP measure.
CSG believes that excluding certain items in calculating its non-GAAP financial measures provides meaningful supplemental information regarding CSG's performance and these items are excluded for the following reasons:
Transaction fees are primarily comprised of fees paid to third-party payment processors and financial institutions and interchange fees under CSG's payment services contracts. Transaction fees are included in revenue in CSG's Income Statement (and not netted against revenue) because CSG maintains control and acts as principal over the integrated service provided under its payment services customer contracts. However, CSG excludes expense associated with transaction fees from the numerator and denominator in calculating its non-GAAP adjusted operating margin percentage in order to provide comparability with historical and future periods and with its peer group and competitors.
Restructuring and reorganization charges are expenses that result from cost reduction initiatives and/or significant changes to CSG's business, to include such things as involuntary employee terminations, changes in management structure, divestitures of businesses, facility consolidations and abandonments, and fundamental reorganizations impacting operational focus and direction. These charges are not considered reflective of CSG's recurring business operating results. The exclusion of these items in calculating CSG's non-GAAP financial measures allows management and investors an additional means to compare CSG's current financial results with historical and future periods.
Executive transition costs include expenses incurred related to a departure of a CSG executive officer under the terms of the related separation agreement. These types of costs are not considered reflective of CSG's recurring business operating results. The exclusion of these costs in calculating CSG's non-GAAP financial measures allows management and investors an additional means to compare CSG's current financial results with historical and future periods.
Acquisition-related expenses include amortization of acquired intangible assets, earn-out compensation, and transaction-related costs. Transaction-related costs, which typically include expenses related to legal, accounting, and other professional services, are direct and incremental expenses related to business acquisitions, and thus, are not considered reflective of CSG's recurring business operating results. The total amount of acquisition-related expenses can vary significantly between periods based on the number and size of acquisition activities, previously acquired intangible assets becoming fully amortized, and ultimate realization of earn-out compensation. In addition, the timing of these expenses may not directly correlate with underlying performance of the CSG's operations. Therefore, the exclusion of acquisition-related expenses in calculating CSG's non-GAAP financial measures allows management and investors an additional means to compare CSG's current financial results with historical and future periods.
Stock-based compensation results from CSG's issuance of equity awards to its employees under incentive compensation programs. The amount of this incentive compensation in any period is not generally linked to the level of performance by employees or CSG. The exclusion of these expenses in calculating CSG's non-GAAP financial measures allows management and investors an additional means to evaluate the non-cash expense related to compensation included in CSG's results of operations, and therefore, the exclusion of this item allows investors to further evaluate the cash generating capabilities of CSG's business.
Gains and losses related to the extinguishment/conversion of debt can be as a result of the refinancing of CSG's credit agreement and/or repurchase, conversion, or settlement of CSG's convertible notes. These activities, to include any derivative activity related to debt conversions, are not considered reflective of CSG's recurring business operating results. Any resulting gain or loss is generally non-cash income or expense, and therefore, the exclusion of these items allows investors to further evaluate the cash impact of these activities for cash flow and liquidity purposes. In addition, the exclusion of these gains and losses in calculating CSG's non-GAAP EPS allows management and investors an additional means to compare CSG's current operating results with historical and future periods.
Gains or losses related to the acquisition or disposition of certain of CSG's business activities are not considered reflective of CSG's recurring business operating results. Any resulting gain or loss is generally non-cash income or expense, and therefore, the exclusion of these items allows investors to further evaluate the cash impact of these activities for cash flow and liquidity purposes. In addition, the exclusion of these gains and losses in calculating CSG's non-GAAP EPS allows management and investors an additional means to compare CSG's current operating results with historical and future periods.
Unusual items within CSG's quarterly and/or annual income tax expense can occur from such things as income tax accounting timing matters, income taxes related to unusual events, or as a result of different treatment of certain items for book accounting and income tax purposes. Consideration of such items in calculating CSG's non-GAAP financial measures allows management and investors an additional means to compare CSG's current financial results with historical and future periods.
CSG also reports non-GAAP adjusted EBITDA and non-GAAP adjusted free cash flow. Management believes non-GAAP adjusted EBITDA is a useful measure to investors in evaluating CSG's operating performance, debt servicing capabilities, and enterprise valuation. CSG defines non-GAAP adjusted EBITDA as income before interest, income taxes, depreciation, amortization, stock-based compensation, foreign currency transaction adjustments, acquisition-related expenses, and unusual items, such as restructuring and reorganization charges, executive transition costs, gains and losses related to the extinguishment of debt, and gains and losses on acquisitions or dispositions, as discussed above. Additionally, management uses non-GAAP adjusted free cash flow, among other measures, to assess its financial performance and cash generating capabilities, and believes that it is useful to investors because it shows CSG's cash available to service debt, make strategic acquisitions and investments, repurchase its common stock, pay cash dividends, and fund ongoing operations. CSG defines non-GAAP adjusted free cash flow as net cash flows from operating activities before earn-out compensation payments related to acquisitions less the purchases of software, property, and equipment.
The reconciliation of GAAP operating income to non-GAAP operating income, and calculation of CSG's non-GAAP adjusted operating margin percentage, for the indicated periods are as follows (in thousands, except percentages):
(1)
Restructuring and reorganization charges include stock-based compensation, which is not included in the stock-based compensation line in the tables above and following, and depreciation, which has not been recorded to the depreciation line item on CSG's Income Statement.
(2)
Transaction fees are primarily comprised of fees paid to third-party payment processors and financial institutions and interchange fees under CSG's payment services contracts. Transaction fees are included in revenue in CSG's Income Statement (and not netted against revenue) because CSG maintains control and acts as principal over the integrated service provided under its payment services customer contracts. However, CSG excludes expense associated with transaction fees from the numerator and denominator in calculating its non-GAAP adjusted operating margin percentage in order to provide comparability with historical and future periods and with its peer group and competitors.
Expand
Non-GAAP EPS:
The reconciliations of GAAP EPS to non-GAAP EPS for the indicated periods are as follows (in thousands, except per share amounts):
(3)
For the quarters ended March 31, 2025 and 2024, the GAAP effective income tax rates were approximately 25% and 29%, respectively, and the non-GAAP effective income tax rates were 27.0% and 28.5%, respectively.
(4)
The outstanding diluted shares for the quarters ended March 31, 2025 and 2024 were 28.3 million and 28.8 million, respectively.
Expand
Non-GAAP Adjusted EBITDA:
CSG's calculation of non-GAAP adjusted EBITDA and the reconciliation of CSG's non-GAAP adjusted EBITDA measure to GAAP net income is provided below for the indicated periods (in thousands, except percentages):
(5)
Interest expense includes amortization of deferred financing costs as provided in Note 6 below.
(6)
Amortization on the statement of cash flows is made up of the following items for the indicated periods (in thousands):
Expand
Non-GAAP Adjusted Free Cash Flow:
CSG's calculation of non-GAAP adjusted free cash flow and the reconciliation of CSG's non-GAAP adjusted free cash flow measure to cash flows from operating activities are provided below for the indicated periods (in thousands):
Non-GAAP Financial Measures – 2025 Financial Guidance
The reconciliation of GAAP operating income to non-GAAP operating income, and calculation of non-GAAP adjusted operating margin percentage, as included in CSG's 2025 full year financial guidance, is as follows (in thousands, except percentages):
Non-GAAP EPS:
The reconciliation of GAAP EPS to non-GAAP EPS as included in CSG's 2025 full year financial guidance is as follows (in thousands, except per share amounts):
2025 Guidance Range
Amounts
EPS (8)
Amounts
EPS (8)
GAAP net income
$
79,300
$
2.86
$
87,200
$
3.13
GAAP income tax provision (7)
30,800
33,900
GAAP income before income taxes
110,100
121,100
Restructuring and reorganization charges
12,400
12,400
Acquisition-related expenses:
Amortization of acquired intangible assets
13,800
13,800
Earn-out compensation
7,900
7,900
Stock-based compensation
34,300
34,300
Loss on debt extinguishment
500
500
Non-GAAP income before income taxes
179,000
190,000
Non-GAAP income tax provision (7)
(50,100
)
(53,100
)
Non-GAAP net income
$
128,900
$
4.65
$
136,900
$
4.90
Expand
(7)
For 2025, the estimated effective income tax rates for GAAP and non-GAAP purposes are both expected to be approximately 28%.
(8)
The weighted-average diluted shares outstanding are expected to be approximately 28 million.
Expand
Non-GAAP Adjusted EBITDA:
CSG's calculation of non-GAAP adjusted EBITDA and the reconciliation of CSG's non-GAAP adjusted EBITDA measure to GAAP net income is provided below for CSG's 2025 full year financial guidance (in thousands, except percentages):
2025 Guidance Range
Low Range
High Range
GAAP net income
$
79,300
$
87,200
GAAP income tax provision (7)
30,800
33,900
Interest expense
29,500
29,500
Loss on debt extinguishment
500
500
Interest income
(5,400
)
(5,400
)
GAAP operating income
134,700
145,700
Restructuring and reorganization charges
12,400
12,400
Acquisition-related expenses:
Amortization of acquired intangible assets
13,800
13,800
Earn-out compensation
7,900
7,900
Stock-based compensation
34,300
34,300
Amortization of other intangible assets
10,700
10,700
Amortization of client contract costs
22,600
22,600
Depreciation
21,600
21,600
Non-GAAP adjusted EBITDA
$
258,000
$
269,000
Non-GAAP adjusted EBITDA as a percentage of revenue less
transaction fees (2)
23.4
%
23.6
%
Expand
Non-GAAP Adjusted Free Cash Flow:
CSG's calculation of non-GAAP adjusted free cash flow and the reconciliation of CSG's non-GAAP adjusted free cash flow measure to cash flows from operating activities is provided below for CSG's 2025 full year financial guidance (in thousands):

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
2 hours ago
- Business Wire
Resecurity Expands LATAM Presence Through Strategic Partnership with INFORC in Ecuador
LOS ANGELES & QUITO, Ecuador--(BUSINESS WIRE)-- Resecurity, a U.S.-based cybersecurity and threat intelligence company, is pleased to announce a new strategic partnership with INFORC ECUADOR, a leading Ecuadorian cybersecurity company that specializes in offering cybersecurity solutions and services to organizations across the region. This partnership marks a key development in Resecurity's expansion strategy across Latin America, solidifying its presence in Ecuador and further enhancing the availability of its advanced threat intelligence and cybersecurity solutions to local organizations. Founded in 2005, INFORC ECUADOR® is widely recognized for its expertise in information security compliance, secure software development, incident response (CSIRT), and offensive security testing. As a reseller of Resecurity's cybersecurity solutions, INFORC will help local organizations strengthen their cybersecurity posture by delivering Resecurity's state-of-the-art products, including the Context™ threat intelligence platform, advanced endpoint protection, and fraud prevention solutions. Through this partnership, INFORC will: Offer Resecurity's market-leading cyber threat intelligence and fraud prevention solutions to Ecuadorian enterprises and government entities. Deliver expert services related to Resecurity's platform implementation, training, and support. Collaborate with Resecurity to offer cybersecurity compliance, incident response, and intelligence services tailored to Ecuador's regulatory environment. Provide enhanced threat detection, phishing prevention, malware tracking, and brand abuse protection solutions. "Our partnership with Resecurity is a significant milestone in our mission to deliver cutting-edge cybersecurity solutions to Ecuador," said Ing. Carlos Jumbo, CEO of INFORC. "By reselling Resecurity's solutions, we can offer our clients world-class cyber threat intelligence and risk management capabilities to help them secure their operations and meet compliance requirements." "We are thrilled to partner with INFORC to bring our advanced cybersecurity solutions to Ecuador," said Gene Yoo, CEO of Resecurity."This partnership helps us further extend our presence in Latin America and equips INFORC with the tools and expertise needed to help local organizations defend against increasingly sophisticated cyber threats." The collaboration is poised to address the growing demand for cybersecurity solutions in Ecuador, especially in light of rising cyber threats targeting both public and private sector entities. INFORC's trusted status in the region, combined with Resecurity's innovative technology, will provide Ecuadorian organizations with the advanced tools necessary to proactively manage and mitigate digital risks. With this agreement, Resecurity continues its commitment to building strong relationships with regional partners across Latin America, reinforcing its role as a key player in the cybersecurity space. About Resecurity® Resecurity® is a cybersecurity company that delivers a unified endpoint protection, fraud prevention, risk management, and cyber threat intelligence platform. Known for providing best-of-breed data-driven intelligence solutions, Resecurity's services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, by Inc. Magazine, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California. As a member of InfraGard National Members Alliance (INMA), AFCEA, NDIA, SIA, FS-ISAC, and the American Chamber of Commerce in Saudi Arabia (AmChamKSA), Singapore (AmChamSG), Korea (AmChamKorea), Mexico (AmChamMX), Thailand (AmChamThailand), and UAE (AmChamDubai). To learn more about Resecurity, visit About INFORC ECUADOR® Founded in 2005, INFORC ECUADOR® is a leading Ecuadorian cybersecurity company recognized for its expertise in providing comprehensive cybersecurity services and solutions. With a strong presence in the local market, INFORC specializes in areas such as information security compliance, secure software development, incident response, penetration testing, phishing detection, and cyber intelligence services. The company also offers cybersecurity training, awareness programs, and operates a Computer Security Incident Response Team (CSIRT). INFORC's in-depth knowledge of the Ecuadorian market and its commitment to delivering top-tier security solutions make it a trusted partner for both private and public sector organizations. Learn more at


Business Wire
3 hours ago
- Business Wire
Cosmetics Industry Icon Leonard A. Lauder, Chairman Emeritus, The Estée Lauder Companies, Passes Away
NEW YORK--(BUSINESS WIRE)--It is with deep sadness that The Estée Lauder Companies Inc. (NYSE: EL) announces that Chairman Emeritus Leonard A. Lauder passed away on June 14, at the age of 92, surrounded by family. Mr. Lauder was born in 1933 in New York City, the oldest son of Estée and Joseph H. Lauder, the founders of The Estée Lauder Companies. He was a graduate of the Bronx High School of Science, the University of Pennsylvania's Wharton School, and the Officer Candidate School of the United States Navy. Mr. Lauder studied at Columbia University's Graduate School of Business. He served as a lieutenant in the U.S. Navy and as a Navy reservist, for which the U.S. Navy Supply Corps Foundation later recognized him with its Distinguished Alumni Award. He formally joined Estée Lauder in 1958, and for more than six decades, Mr. Lauder was a visionary and an innovator, helping transform the business from a handful of products sold under a single brand in U.S. stores to the multi-brand, global leader in prestige beauty that it is today. 'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' said William P. Lauder, son and Chair, Board of Directors, The Estée Lauder Companies. 'He was the most charitable man I have ever known, believing that art and education belonged to everyone, and championing the fight against diseases such as Alzheimer's and breast cancer. Above all, my father was a man who practiced kindness with everyone he met. His impact was enormous. He believed that employees were the heart and soul of our company, and they adored him and moments spent with him. His warmth and thoughtfulness made an imprint on our company, the industry, and, of course, our family. Together with my family, The Estée Lauder Companies, and the countless people he touched, we celebrate his extraordinary life.' Mr. Lauder served as President of The Estée Lauder Companies from 1972 to 1995 and as Chief Executive Officer from 1982 through 1999. He was named Chairman in 1995 and served in that role through June 2009. Throughout his tenure at the company, Mr. Lauder consistently challenged the status quo, developing and implementing innovative sales and marketing programs that revolutionized the beauty industry. He created the company's first research and development laboratory, brought in professional management at every level, and was the driving force behind The Estée Lauder Companies' international expansion, helping to increase the company's sales and profits exponentially. A legendary brand builder, Mr. Lauder led the launch of many brands including Aramis, Clinique, and Lab Series, among others. Until his death, he remained deeply involved in the company's acquisition strategy, including the acquisitions of Aveda, Bobbi Brown, Jo Malone London, La Mer, and M∙A∙C. Speaking for The Estée Lauder Companies, President and Chief Executive Officer Stéphane de La Faverie said, 'Leonard Lauder was beloved by many and will be missed tremendously. To our employees at The Estée Lauder Companies, he was an inspiration and a champion. To the industry, he was an icon and pioneer, earning respect worldwide. His energy and vision helped shape our company and will continue to do so for generations to come. He was a deeply compassionate leader who cared profoundly about every person in the company. I feel privileged to have worked with Leonard, who has been the best mentor I could have dreamt to learn from. He will be remembered by all of us.' During his many years as Chairman Emeritus, Mr. Lauder was closely involved in the business and day-to-day operations of the company and was a constant fixture at The Estée Lauder Companies' global headquarters in New York and at our stores and counters across the globe until the time of his death. Mr. Lauder believed that each of his colleagues was like a member of his family and treated them as such. The values that continue to set the company apart are the values he so strongly believed in and embodied, most notably generosity of spirit and kindness toward all. Perhaps the role Mr. Lauder was most proud of was the unofficial one as The Estée Lauder Companies' 'chief teaching officer.' He believed that a company's wealth is its people and focused on mentoring and fostering growth within the company's diverse talent pool. He believed strongly in the importance of recognition and gratitude and was a tireless advocate for employees. At the onset of the global pandemic in 2020, Mr. Lauder was instrumental in setting up the ELC Cares Employee Relief Fund to support the physical, mental, and emotional well-being of employees and their families. Mr. Lauder was deeply involved in medical research, education, art, foreign policy, and philanthropy, and the marks he made on those worlds were transformational. Mr. Lauder believed passionately in the importance of public access to art and museums, which inspired his philosophy that the primary role of a collector was to conserve, not possess. He was a long-time supporter of the Metropolitan Museum of Art (the Met) and, in 2013, pledged his 78-piece collection of Cubist art to the museum in the largest single philanthropic gift in the Met's history. He later added five major works to that promised gift. In concert with his Cubist collection donation, he helped establish the Leonard A. Lauder Research Center for Modern Art at the Met to support a robust program of fellowships, focused exhibitions, and public lectures. Along with his prominent presence at the Met, he also served as the Whitney Museum of American Art's Chairman Emeritus and a trustee from 1977 to 2011. Throughout his life, he donated works of art and endowed curatorial positions and research departments to numerous institutions. Mr. Lauder was a long-time advocate of cancer research and served as Honorary Chairman of the board of directors at the Breast Cancer Research Foundation, the organization his beloved late-wife, Evelyn H. Lauder, founded in 1993. He also championed the fight against Alzheimer's by co-founding and leading the Alzheimer's Drug Discovery Foundation with his brother, Ronald S. Lauder, which supports cutting-edge drug research. Mr. Lauder remained actively engaged with these organizations until his death, and they were extraordinarily dear to his heart. Remembering his brother, Ronald S. Lauder, Chairman, Clinique Laboratories, LLC at The Estée Lauder Companies, said, 'Leonard was a wonderful brother and a devoted husband, father, grandfather, great-grandfather, uncle, colleague, and friend. But his legacy extends far beyond being the heart of our family. His impact will be felt for generations to come thanks to his tireless philanthropy, advocacy, and creativity in tackling some of the world's greatest challenges. The number of lives he touched and positively impacted across all his endeavors is immeasurable. His passion and generosity have inspired us all, and there are no words to express how much he will be missed.' 'My father was a remarkable man, a leader in business, a devoted philanthropist, and a deeply loving father, grandfather, and great-grandfather,' said Gary M. Lauder, son and Member, Board of Directors, The Estée Lauder Companies. 'His energy, sharp intellect, and generous spirit touched the lives of so many across the world. To me, he was also a constant source of encouragement, wisdom, and love. His legacy is vast, not only in the beauty industry, but in the countless lives improved by his charitable efforts and his passionate commitment to the arts, education, and healthcare. He was not only well-respected and admired, but he was also adored by his employees and colleagues. This affection stands out for me. While we mourn his passing, we also celebrate his extraordinary life, his lasting contributions, and the values he instilled in all of us: integrity, curiosity, and the importance of giving back. He will be missed more than words can express.' Mr. Lauder believed in the value of education and supported a variety of academic institutions. He was an emeritus trustee of the University of Pennsylvania and a founding member of the board of governors of its Joseph H. Lauder Institute of Management and International Studies, along with his brother, Ronald. His passion for education continued into the public space, having supported several schools in the New York area and receiving the honor of being an inductee into the Bronx High School of Science Hall of Fame in 2017. When the pandemic in 2020 magnified the nation's acute shortage of quality primary care in underserved communities, Mr. Lauder worked with the University of Pennsylvania to create a tuition-free program to educate nurse practitioners. His donation of $125 million, the largest gift ever to an American nursing school, made possible the Leonard A. Lauder Community Care Nurse Practitioner Program at the University of Pennsylvania. Mr. Lauder worked throughout his life to promote dialogue among governments, political and non-governmental organizations, and the public and private sectors, believing that this interdisciplinary dialogue is crucial to progress. He served as a member of the Council on Foreign Relations and as Chairman Emeritus and a lifetime trustee on the board of directors at the Aspen Institute. He felt that public service was a person's duty and, in addition to his time in the U.S. Navy, later served on the Advisory Committee for Trade Negotiations under President Ronald Reagan from 1983–1987. Throughout his lifetime, Mr. Lauder was honored with a myriad of awards, including the 'Lone Sailor' Award given by the U.S. Navy Supply Corps Foundation, the Légion d'Honneur given by the government of France, the Women's Leadership Award given by the Lincoln Center Corporate Fund Women's Leadership Council, and the Palazzo Strozzi Renaissance Man of the Year Award. In 2020, he was inducted into the Retail Hall of Fame by the World Retail Congress. The Lauder family received the esteemed 2011 Carnegie Medal of Philanthropy in recognition of its long-standing commitment to philanthropy and public service. In 2014, Mr. Lauder was named a Living Landmark by the New York Landmarks Conservancy. Mr. Lauder and Ms. Glickman Lauder also received the Gordon Parks Foundation Patron of the Arts Award in 2016. Mr. Lauder shared many of the lessons he learned in business and life in his memoir, The Company I Keep: My Life in Beauty, published to great acclaim in 2020. He was married to Evelyn H. Lauder, Senior Corporate Vice President at The Estée Lauder Companies and the Founder of the Breast Cancer Research Foundation, from 1959 until she passed away in 2011. On January 1, 2015, Mr. Lauder married Judy Glickman Lauder, a philanthropist and internationally recognized photographer whose work is represented in more than 300 public and private collections, including the J. Paul Getty Museum, the Whitney Museum of Art, the Metropolitan Museum of Art, and the United States Holocaust Museum. Mr. Lauder considered himself lucky in love and believed that lightning really could strike twice. From the beginning, he was devoted to family. He loved his parents and adored his brother, Ronald, and the family Ronald built with Jo Carole. His nieces and their families held a special place in his heart. Mr. Lauder was grateful to his wife, Judy, for widening his family circle and cherished his stepchildren and their families. But mostly, he was extraordinarily proud of both of his sons, their families, and his grandchildren and great-grandchildren. He loved them so dearly. Mr. Lauder was a true visionary, fearless leader, and cherished friend to so many. He was the beacon of our company and the north star of an entire industry. The world is a better place because Leonard Lauder was in it. The Estée Lauder Companies extends our deepest sympathies to the entire Lauder family during this exceedingly difficult time. Mr. Lauder is survived by his wife, Judy Glickman Lauder; his son William P. Lauder; his son Gary M. Lauder and wife, Laura Lauder; five grandchildren, Rachel, Danielle, Djuna-Bear, Joshua, Eliana, two great-grandchildren, many stepchildren and step grandchildren, as well as his brother, Ronald S. Lauder, and wife, Jo Carole Lauder, and their daughters, Aerin Lauder and Jane Lauder. A private service will be held for friends and family. For those who wish, in lieu of flowers, memorial donations may be made to the Breast Cancer Research Foundation and the Alzheimer's Drug Discovery Foundation. The Estée Lauder Companies Inc. (ELC) is one of the world's leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company's products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.


Business Wire
12 hours ago
- Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine